Business context and reporting period
Entity discrepancy: The request identifies Quince Therapeutics, Inc., but the supplied Form 10-Q is for Cortexyme, Inc. (ticker CRTX). This summary reflects the filing text, which covers the quarter ended June 30, 2021, and was signed August 6, 2021.
Cortexyme was a clinical-stage biopharmaceutical company with no product revenue. Its lead candidate, atuzaginstat (COR388), was being studied for Alzheimer’s disease; the company also reported development programs in periodontal disease, Parkinson’s disease and coronavirus infections.
Financial results and liquidity
Amounts below are in millions of dollars, except per-share data. No revenue or gross margin was reported; the company had no commercial product sales.
| Metric | Q2 2021 | Q2 2020 | Six months 2021 | Six months 2020 |
|---|---|---|---|---|
| Research and development expense | $14.7 | $14.1 | $31.5 | $28.5 |
| General and administrative expense | $7.1 | $4.2 | $13.6 | $7.7 |
| Total operating expenses | $21.8 | $18.3 | $45.1 | $36.1 |
| Net loss | $21.8 | $17.6 | $44.8 | $34.8 |
| Basic and diluted loss per share | $0.74 | $0.60 | $1.52 | $1.21 |
| Operating cash used | Not provided for quarter | Not provided for quarter | $31.2 | $25.2 |
At June 30, 2021, cash and cash equivalents were $74.0 million, short-term investments $55.9 million and long-term investments $23.5 million. Total cash, cash equivalents and investments were $153.5 million; current assets were $135.8 million and current liabilities $18.5 million. The company reported no debt; operating lease liabilities totaled $1.5 million. Accumulated deficit was $191.5 million.
Six-month investing cash flow was positive $37.3 million, mainly reflecting $62.6 million of investment maturities against $25.2 million of purchases. Financing cash flow was $1.1 million, primarily option exercises; the comparable 2020 period included $117.6 million in net private-placement proceeds. Stock-based compensation was $13.7 million for the six months, versus $5.4 million a year earlier.
Material changes versus the prior comparable period
- Q2 net loss increased $4.1 million year over year; six-month net loss increased $10.1 million. Higher general and administrative costs and personnel-related and stock-based compensation contributed to the increase.
- Six-month R&D expense rose 10.8%, although atuzaginstat costs fell $5.8 million as manufacturing and trial costs declined. COR588 development and personnel costs increased.
- Cash used in operations rose to $31.2 million from $25.2 million for the first half. The investment portfolio shifted toward cash and shorter-term holdings: short-term investments declined from $67.0 million at year-end 2020 to $55.9 million, and long-term investments from $50.5 million to $23.5 million.
- Interest income fell to $0.4 million for the first half from $1.3 million, reflecting lower average balances and yields.
Outlook, management commentary and key risks
- Management expected topline results from the fully enrolled, 643-subject GAIN Phase 2/3 Alzheimer’s trial in Q4 2021. A separate REPAIR periodontal-disease substudy was also expected to report in Q4 2021.
- The FDA had placed a partial clinical hold on the atuzaginstat open-label extension after reviewing hepatic adverse events. No new participants could enter the extension, and enrolled participants were discontinued; participants in the randomized, double-blind GAIN phase continued treatment. The filing says the hepatic events were reversible and without known long-term adverse effects.
- The company expected to begin COR588 Phase 1 studies in Q3 2021 and reported start-up activities for a Parkinson’s Phase 2 study. These were expectations, not reported outcomes.
- Liquidity runway statements differ within the filing: the financial-statement note says available cash, cash equivalents and short-term investments were expected to fund planned operations for at least 12 months from issuance of the statements; MD&A says cash, cash equivalents and investments were expected to fund operations through 2023, including through GAIN topline results. Management cautioned that assumptions could prove wrong and additional funding might be needed.
- Key risks include uncertain clinical efficacy and safety, FDA review and approval, the hepatic safety issue and other clinical holds, reliance on atuzaginstat, future financing needs, competition, manufacturing and trial execution, and possible COVID-19-related disruption. Management reported no significant operational or material financial impact from COVID-19 to date and said GAIN enrollment was complete.
- The filing reports no material legal proceedings and no off-balance-sheet arrangements. Management concluded disclosure controls and procedures were effective as of June 30, 2021.
Most important facts for investors to verify
- Confirm the intended issuer: the supplied filing is Cortexyme, Inc., not Quince Therapeutics, Inc.
- Check the eventual GAIN and REPAIR results against the stated Q4 2021 expectations, and assess the final data and any subsequent regulatory developments.
- Follow FDA actions on the atuzaginstat partial clinical hold, including the hepatic adverse-event findings and implications for the broader development program.
- Reconcile the filing’s differing cash-runway statements and monitor actual spending, financing needs and investment balances.
- Review the general and administrative expense comparison: the table shows a Q2 year-over-year increase of about $2.9 million, while the accompanying narrative describes an increase of $2.3 million.